KR900007421A - 급성 및 만성 폐쇄성 기도 질환 치료제. - Google Patents

급성 및 만성 폐쇄성 기도 질환 치료제. Download PDF

Info

Publication number
KR900007421A
KR900007421A KR1019890016583A KR890016583A KR900007421A KR 900007421 A KR900007421 A KR 900007421A KR 1019890016583 A KR1019890016583 A KR 1019890016583A KR 890016583 A KR890016583 A KR 890016583A KR 900007421 A KR900007421 A KR 900007421A
Authority
KR
South Korea
Prior art keywords
dihydro
methyl
dibenz
chronic obstructive
airway disease
Prior art date
Application number
KR1019890016583A
Other languages
English (en)
Inventor
에버라인 볼프강
엔겔 볼프하르트
밈 게르하르트
루돌프 클라우스
도즈 헨리
마이어 노르베르트
Original Assignee
디이터 라우딘, 게르하르트 후버
닥터 칼 토매 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디이터 라우딘, 게르하르트 후버, 닥터 칼 토매 게엠베하 filed Critical 디이터 라우딘, 게르하르트 후버
Publication of KR900007421A publication Critical patent/KR900007421A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

급성 및 만성 폐쇄성 기도 질환 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 급성 및 만성 폐쇄성 기도 질환을 치료하기 위한, 5, 11-디하이드로-11-[[(1-메틸-4-피페리디닐)아미노]카보닐]-6H-디벤즈[b,e]아제핀-6-온 및/또는 5, 11-디하이드로-11-[(1-메틸-4-피페라지닐)아세틸]-6H-디벤즈[b,e]아제핀-6-온, 및/는 5, 11-디하이드로-11-[(4-메틸-1-피페라이닐)]-6H-디벤즈[b,e]아제핀-6-온, 생리학적으로 활성인 이의 에난티오머 또는 생리학적으로 허용되는 이의 무기 또는 유기 산과의 염의 용도.
  2. 급성 및 만성 폐쇄성 기도 질환을 치료하기 약제를 제조하기 위한, 5, 11-디하이드로-11-[[(1-메틸-4-피페리디닐)아미노]카보닐]-6H-디벤즈[b,e]아제핀-6-온 및/또는 5, 11-디하이드로-11-[(1-메틸-4-피페라지닐)아세틸]-6H-디벤즈[b,e]아제핀-6-온, 및/는 5, 11-디하이드로-11-[(4-메틸-1-피페라지닐)아세틸]-6H-디벤즈[b,e]아제핀-6-온, 생리학적으로 활성인 이의 에난티오머 또는 생리학적으로 허용되는 이의 무기 또는 유기 산과의 염의 용도.
  3. 제1항 또는 2항에 있어서, 천식, 만성기관지염 및 기종을 억제하기 위한 언급된 화합물의 용도.
  4. 급성 및 만성 폐쇄성 기도 질환을 치료하기 위한, (+)-5, 11-디하이드로-11-[[(1-메틸-4-피페리디닐)아미노]카보닐]-6H-디벤즈[b,e]아제핀-6-온 또는 생리학적으로 허용되는 이의 무기 또는 유기 산과의 염의 용도.
  5. 급성 및 만성 폐쇄성 기도 질환을 치료하는 약제를 제조하기 위한, (+)-5, 11-디하이드로-11-[[(1-메틸-4-피페리디닐)아미노]카보닐]-6H-디벤즈[b,e]아제핀-6-온 또는 생리학적으로 허용되는 이의 무기 또는 유기 산과의 염의 용도.
  6. 제4항에 있어서, 천식, 만성기관지염 및 기종을 억제하기 위한 언급된 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890016583A 1988-11-17 1989-11-16 급성 및 만성 폐쇄성 기도 질환 치료제. KR900007421A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3838912A DE3838912A1 (de) 1988-11-17 1988-11-17 Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen
DEP3838912.6 1988-11-17

Publications (1)

Publication Number Publication Date
KR900007421A true KR900007421A (ko) 1990-06-01

Family

ID=6367356

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890016583A KR900007421A (ko) 1988-11-17 1989-11-16 급성 및 만성 폐쇄성 기도 질환 치료제.

Country Status (13)

Country Link
US (1) US5011836A (ko)
EP (1) EP0369286A3 (ko)
JP (1) JPH02180829A (ko)
KR (1) KR900007421A (ko)
AU (1) AU618422B2 (ko)
CA (1) CA2002980A1 (ko)
DE (1) DE3838912A1 (ko)
DK (1) DK574289A (ko)
HU (1) HU203283B (ko)
IL (1) IL92314A0 (ko)
NZ (1) NZ231403A (ko)
PH (1) PH27084A (ko)
ZA (1) ZA898741B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863492B1 (ko) * 2007-06-05 2008-10-14 주식회사 오에스티 플라즈마 디스플레이 패널의 형광체 세정 방법 및 그 장치

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319077A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6433165B1 (en) * 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204157A1 (de) * 1982-02-06 1983-08-11 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte dibenzodiazepinone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE3402060A1 (de) * 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863492B1 (ko) * 2007-06-05 2008-10-14 주식회사 오에스티 플라즈마 디스플레이 패널의 형광체 세정 방법 및 그 장치

Also Published As

Publication number Publication date
AU4476089A (en) 1990-05-24
DK574289A (da) 1990-05-18
HUT51898A (en) 1990-06-28
AU618422B2 (en) 1991-12-19
PH27084A (en) 1993-02-19
EP0369286A2 (de) 1990-05-23
HU895932D0 (en) 1990-02-28
ZA898741B (en) 1991-07-31
DK574289D0 (da) 1989-11-16
US5011836A (en) 1991-04-30
HU203283B (en) 1991-07-29
NZ231403A (en) 1992-06-25
JPH02180829A (ja) 1990-07-13
EP0369286A3 (de) 1992-01-02
CA2002980A1 (en) 1990-05-17
IL92314A0 (en) 1990-07-26
DE3838912A1 (de) 1990-05-23

Similar Documents

Publication Publication Date Title
MX9200269A (es) Derivados de bifenilo, medicamentos que contienen estos compuestos y procedimientos para su preparacion
MX9302448A (es) Derivados iminicos ciclicos, procedimientos para su preparacion y medicamentos que contienen estos compuestos.
BG102202A (en) Enantiomer and ipratropiumbromide with extended effect
HUP9801220A2 (hu) Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerkészítmények előállítására
CA2344407A1 (en) Method for the treatment of mania and bipolar disorder
KR900007421A (ko) 급성 및 만성 폐쇄성 기도 질환 치료제.
KR910000158A (ko) 의약용 화합물 및 그것의 사용방법
ZA963826B (en) A method of treatment of mania and bipolar disorder
ATE174508T1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
KR880013555A (ko) 당뇨병의 치료방법
MX9302459A (es) Derivados imino ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
DE69508551D1 (de) Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
MY114428A (en) New pharmacological use of aii-receptor antagonists
MD586C2 (ro) Substanţă medicamentoasă cu acţiune antihipotensivă "Difetur"
ATE237619T1 (de) Sesquiterpen-derivate mit antiviraler aktivität
ITTO930661A0 (it) Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
ATE96025T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
KR920703067A (ko) 말초 신경질환 및 뇌질환 치료용 L-α-글리세로포르포릴-D-미오-이노시톨
ID15889A (id) Asam tiofenilakenilkarboksilat guanidida tersubtitusi proses pembuatannya, penggunaannya sebagai suatu obat atau diagnostik dan suatu obat yang mengandungnya
KR920007626A (ko) 벤조[b]티오펜-2-카르복시이미드아미드 유도체의 사용방법
KR890007742A (ko) 허혈성 심장 질환 치료제
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
TH17660A (th) สารผสมสำหรับป้องกันและรักษาสายตาสั้น
JPS5661357A (en) Benzazepin derivative* its manufacture and medicinal composition containing it

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid